rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG

NCT ID: NCT04943848

Last Updated: 2024-08-21

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE1
• Total Enrollment: 36 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-01-10
• Study Completion Date: 2025-12-31

Brief Summary

This is a phase I, open label, plus expansion clinical trial evaluating the safety and tolerability of rHSC-DIPGVax in combination with BALSTILIMAB and ZALIFRELIMAB. rHSC-DIPGVax is an off-the-shelf neo-antigen heat shock protein containing 16 peptides reflecting neo-epitopes found in the majority of DIPG and DMG tumors. Newly diagnosed patients with DIPG and DMG who have completed radiation six to ten weeks prior to enrollment are eligible.

Detailed Description

This is a phase I, open label, plus expansion clinical trial evaluating the safety and tolerability of rHSC-DIPGVax in combination with BALSTILIMAB and ZALIFRELIMAB using a 3+3 design for subjects with newly diagnosed DIPG or DMG following completion of radiation therapy. Given this is a first in-human study of rHSC-DIPGVax, an initial study "Lead In" will assess the tolerability of vaccine monotherapy first in older children (ages 5 to 18 years of age) followed by younger children (12 months to 18 years of age).

Sequential Parts A and B of this study will also first enroll patients ages 5 to 18 years of age before enrolling younger children. The rationale for the combination of vaccine and anti-PD1 therapy includes evidence of a more profound intra-tumoral response with addition of inhibition of negative co-regulatory pathways, such as, PD1/PDL1 and the need to overcome potentially immunosuppressive or immune "cold" microenvironment of gliomas. Anti-CLTA4 therapy will also be combined with rHSC-DIPGVax in the dose escalation portion of this study because of the ability of anti-CTLA4 therapy to induce T cell priming to promote T memory formation. Given the lack of standard treatment options for DIPG and DMG patients, this clinical trial will use combinatorial immunotherapy in upfront treatment of these patients in hopes of maximizing potential efficacy in this at-risk population while still assessing safety throughout.

Part A will evaluate rHSC-DIPGVax plus BALSTILIMAB. Pharmacokinetics (PK) of BALSTILIMAB will also be evaluated to assess exposure. If the rHSC-DIPGVax plus BALSTILIMAB is well tolerated in Part A for 28-days, this study will then move to enrolling Part B to evaluate the safety and tolerability of rHSC-DIPGVax and BALSTILIMAB in combination with ZALIFRELIMAB at two dose levels for a total therapy duration of one year or twenty-seven cycles, whichever occurs first.

Advancement from Part A to Part B and dose escalation in Part B will follow a conservative 3+3 design. The dose limiting toxicity (DLT) monitoring period will last 28 days (2 cycles) for Part A subjects and 42 days (1 cycle) for Part B. Subjects will be allowed to continue on in Part A for twenty-seven 14-day cycles or nine 42-day cycles in Part B or 1 year of total therapy, whichever comes first.

After the RP2D of ZALIFRELIMAB is determined, Part C, the expansion arm, will enroll further subjects at this dose level to assess futility versus efficacy. All subjects in trial Part C will be monitored for dose limiting toxicities for the duration of their participation in the study to monitor for excess toxicity.

Conditions

Diffuse Intrinsic Pontine Glioma; Diffuse Midline Glioma, H3 K27M-Mutant

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

"Lead In": rHSC-DIPGVax Monotherapy

rHSC-DIPGVax for 8 total doses

Group Type: EXPERIMENTAL

rHSC-DIPGVax

Intervention Type: BIOLOGICAL

Off-the-shelf, neoantigen heat shock protein vaccine

Part A: rHSC-DIPGVax in Combination with BALSTILIMAB (Anti-PD1)

rHSC-DIPGVax (8 total doses) + BALSTILIMAB (1 year of therapy or 27 cycles, whichever comes first)

Patients will enroll 6-10 weeks post standard of care (SOC) radiation completion. Steroid dose must be at or below 0.5mg/kg/day for a minimum of 7 days. The first 3 patients must be 5 years or older to 18. Subsequently, subjects ages 12 months to 18 years can be enrolled. Up to six patients will be enrolled on Part A. Once safety is established for rHSC-DIPGVax plus anti-PD1 (BALSTILIMAB), the study will proceed to Part B.

Group Type: EXPERIMENTAL

rHSC-DIPGVax

Intervention Type: BIOLOGICAL

Off-the-shelf, neoantigen heat shock protein vaccine

Balstilimab

Intervention Type: DRUG

BALSTILIMAB is a human monoclonal antibody that targets programmed cell death 1 (PD1)

Part B: Dose Escalation of ZALIFRELIMAB (Anti-CTLA4)

rHSC-DIPGVax (8 total doses) + BALSTILIMAB + ZALIFRELIMAB (1 year of therapy or 9 cycles, whichever comes first)

Patients will enroll 6-10 weeks post standard of care (SOC) radiation therapy. Steroid dose must be at or below 0.5mg/kg/day for a minimum of 7 days. The first 3 patients must be 5 years or older to 18. Subsequently, subjects ages 12 months to 18 years can be enrolled. Up to 12 patients will be enrolled on Part B. Once safety is established for rHSC-DIPGVax plus anti-PD1 (BALSTILIMAB) plus anti-CTLA4 (ZALIFRELIMAB), the study will proceed to Part C.

Group Type: EXPERIMENTAL

rHSC-DIPGVax

Intervention Type: BIOLOGICAL

Off-the-shelf, neoantigen heat shock protein vaccine

Balstilimab

Intervention Type: DRUG

BALSTILIMAB is a human monoclonal antibody that targets programmed cell death 1 (PD1)

Zalifrelimab

Intervention Type: DRUG

ZALIFRELIMAB is a human monoclonal immunoglobulin G1k subclass (IgG1k) antibody that specifically recognizes cytotoxic T lymphocyte-associated protein 4 (CTLA-4, also known as CD152)

Part C: Dose Expansion

rHSC-DIPGVax (8 total doses) + BALSTILIMAB + ZALIFRELIMAB (at RP2D from Part B) (1 year of therapy or 9 cycles, whichever comes first)

Patients will enroll 6-10 weeks post standard of care (SOC) radiation therapy. Steroid dose must be at or below 0.5mg/kg/day for a minimum of 7 days. Up to 12 patients will be enrolled on Part C. All subjects in Part C will be monitored for DLT's for the duration of their participation in the study to monitor for excess toxicity.

Group Type: EXPERIMENTAL

rHSC-DIPGVax

Intervention Type: BIOLOGICAL

Off-the-shelf, neoantigen heat shock protein vaccine

Balstilimab

Intervention Type: DRUG

BALSTILIMAB is a human monoclonal antibody that targets programmed cell death 1 (PD1)

Zalifrelimab

Intervention Type: DRUG

ZALIFRELIMAB is a human monoclonal immunoglobulin G1k subclass (IgG1k) antibody that specifically recognizes cytotoxic T lymphocyte-associated protein 4 (CTLA-4, also known as CD152)

Interventions

rHSC-DIPGVax

Off-the-shelf, neoantigen heat shock protein vaccine

Intervention Type: BIOLOGICAL

Balstilimab

BALSTILIMAB is a human monoclonal antibody that targets programmed cell death 1 (PD1)

Intervention Type: DRUG

Zalifrelimab

ZALIFRELIMAB is a human monoclonal immunoglobulin G1k subclass (IgG1k) antibody that specifically recognizes cytotoxic T lymphocyte-associated protein 4 (CTLA-4, also known as CD152)

Intervention Type: DRUG

Other Intervention Names

vaccine; checkpoint blockade; anti-PD1; checkpoint blockade; anti-CTLA4

Eligibility Criteria

Inclusion Criteria

• Subjects with newly diagnosed typical or non-typical, biopsy-proven DIPG or DMG are eligible for study enrollment. Biopsy is not required for subjects with radiographically typical DIPG meeting imaging criteria. Biopsy is required for DMG's and non-radiographically typical DIPG. Histone mutation must be confirmed by pathology report. Radiographically typical DIPG defined as a tumor with a pontine epicenter and diffuse involvement of more than 2/3 of the pons.

= Subjects ages > or = to 12 months and < or = 18 years ("Lead In", Part A, and Part B require first three patients be > or = to 12 years of age)

• BSA > or = 0.35m2 at the time of study enrollment
• Performance score: Karnofsky >50% of subjects >16 years of age and Lansky > or = 50 for subjects < or = 16 years of age. Subjects who are unable to walk because of paralysis but are up in a wheelchair will be considered ambulatory for the purpose of assessing the performance score.
• Must start radiation therapy within 42 days from date of diagnostic imaging. C1D1 must be within 42 days to 70 days post radiation (6-10 weeks). Patients CANNOT receive temozolomide during radiation
• Corticosteroids should be weaned as tolerated after radiation therapy with the goal of < or = 0.5mg/kg/day for a minimum of 7 days prior to enrollment.
• Subjects must have measurable disease

Exclusion Criteria

• Patients cannot receive temozolomide during radiation
• Disseminated disease
• Subjects who have received any cancer therapy except for radiation
• Autoimmune or immune disorders
• Active respiratory disorder or infection
• Active viral infection

• Minimum Eligible Age: 12 Months
• Maximum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Dana-Farber Cancer Institute

OTHER

Sponsor Role: collaborator

Children's Hospital of Orange County

OTHER

Sponsor Role: collaborator

University of Calgary

OTHER

Sponsor Role: collaborator

Ann & Robert H Lurie Children's Hospital of Chicago

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Ashley Plant-Fox, MD

Role: PRINCIPAL_INVESTIGATOR

Ann and Robert H. Lurie Children's Hospital

Locations

Children's Health Orange County (CHOC)

Orange, California, United States

Site Status: RECRUITING

Ann and Robert H. Lurie Children's Hospital of Chicago

Chicago, Illinois, United States

Site Status: RECRUITING

Dana-Farber Boston Children's Cancer and Blood Disorders Center

Boston, Massachusetts, United States

Site Status: RECRUITING

Countries

United States

Central Contacts

Monica Newmark, BS, RN

Role: CONTACT

MNewmark@luriechildrens.org

312-227-4847

Ashley Plant-Fox, MD

Role: CONTACT

aplant@luriechildrens.org

312-227-4858

Facility Contacts

Mariko Sato, MD

Role: primary

mariko.sato@choc.org

714-509-8636

Claudia Mousa

Role: backup

claudia.mousa@choc.org

714-509-8724

Ashley S Plant, MD

Role: primary

aplant@luriechildrens.org

312-227-4090

Monica Newmark, BS

Role: backup

mnewmark@luriechildrens.org

312-227-4847

Alexa E Stathis

Role: primary

alexae_stathis@dfci.harvard.edu

857-215-1558

Susan Chi, MD

Role: backup

susan_chi@dfci.harvard.edu

617-632-4386

Other Identifiers

LCH 20C05

Identifier Type: -

Identifier Source: org_study_id